<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer R Brown, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 25 percent of adult NHL cases. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms"</a>.)</p><p>The molecular pathogenesis of DLBCL is a complex, multistep process that ultimately results in the transformation and expansion of a malignant clone of germinal or post-germinal B cell origin. While some steps in this pathway have been elucidated, many remain unknown. The best-characterized oncogenic events are acquired genetic lesions (eg, rearrangements of <em>BCL6</em>,<em> BCL2</em>,<em> </em>and<em> MYC</em>), many of which are also seen in other NHL variants. This may reflect in part the not uncommon evolution of low-grade lymphoma into DLBCL. (See  <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4724.html" rel="external">"Histologic transformation of follicular lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4728.html" rel="external">"Richter transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p>The following sections will describe genetic changes, aberrant gene and protein expression, and other alterations that are thought to play a role in the development of DLBCL. It is increasingly appreciated that the diagnostic category of "DLBCL" is heterogeneous in terms of morphology, genetics, and biologic behavior. The 2016 World Health Organization classification of lymphoid neoplasms recommends that immunohistochemistry and/or gene expression profiling be used to subclassify "typical" DLBCL into tumors of germinal center and non-germinal center origin, in recognition that these two classes of tumors have different prognoses with current therapies [<a href="#rid1">1</a>]. Most of the non-germinal center tumors fall into a specific category, the activated B cell (ABC) type, so named based on a resemblance to the gene expression signature of normal activated B cells, whereas others fall into an unclassifiable category. In addition, several clinicopathologic entities are recognized that share some features with "typical" DLBCL yet are sufficiently distinct to be considered separate diagnostic and/or therapeutic categories:</p><p class="bulletIndent1"><span class="glyph">●</span>T cell rich large B cell lymphoma. (See  <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary mediastinal large B cell lymphoma. (See  <a class="medical medical_review" href="/z/d/html/4713.html" rel="external">"Primary mediastinal large B cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravascular large B cell lymphoma. (See  <a class="medical medical_review" href="/z/d/html/4738.html" rel="external">"Intravascular large B cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphomatoid granulomatosis, an Epstein-Barr virus (EBV) positive large B cell lymphoma, often occurring at extranodal sites such as the lung, in which the EBV-positive B cells are scarce and the host response in the form of T cells and macrophages makes up the majority of the tumor mass. (See  <a class="medical medical_review" href="/z/d/html/4324.html" rel="external">"Pulmonary lymphomatoid granulomatosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>EBV-positive DLBCL, which resembles typical DLBCL morphologically (unlike lymphomatoid granulomatosis) but demonstrates latent EBV infection in the tumor cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DLBCL associated with <em>IRF4</em> rearrangements, a subtype that is predominantly seen in children and young adults, frequently involves Waldeyer's ring and the gastrointestinal tract, and has an excellent outcome with chemotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DLBCL associated with chronic inflammation, a subtype of DLBCL that arises in the context of local chronic inflammation, often present for many years.</p><p></p><p>This topic will review the pathobiology and genetics of DLBCL and primary mediastinal large B cell lymphoma. General discussions of the pathobiology and specific chromosomal abnormalities seen in NHL subtypes are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4500.html" rel="external">"Genetic abnormalities in hematologic and lymphoid malignancies"</a> and  <a class="medical medical_review" href="/z/d/html/4482.html" rel="external">"General aspects of cytogenetic analysis in hematologic malignancies"</a> and  <a class="medical medical_review" href="/z/d/html/4711.html" rel="external">"Overview of the pathobiology of the non-Hodgkin lymphomas"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CELL OF ORIGIN</span><span class="headingEndMark"> — </span>DLBCL is a heterogeneous clinicopathologic entity that includes tumors derived from germinal center B cells or post-germinal center B cells (also called activated B cells). The germinal center or post-germinal center ancestry of these cells is principally supported by the identification of somatic mutations in the variable region of the immunoglobulin genes (<em>IgVH</em>), which serves as a marker of germinal center transit [<a href="#rid2">2</a>]. The majority of cases also demonstrate ongoing somatic mutations, which reflect the pressure of antigen selection associated with post-germinal center lymphocytes  (<a class="graphic graphic_figure graphicRef80736" href="/z/d/graphic/80736.html" rel="external">figure 1</a>) [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>.)</p><p>Additional information regarding the cell of origin is derived from gene expression profile analyses described in more detail below. (See <a class="local">'Gene expression heterogeneity of DLBCL'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">ABERRANT BCL6 EXPRESSION</span><span class="headingEndMark"> — </span>The majority of DLBCL tumors express the B cell lymphoma 6 (<em>BCL6</em>) gene, which encodes a transcriptional repressor. In normal B cells, BCL6 negatively regulates its own expression by binding to the <em>BCL6</em> promoter. Persistent expression in DLBCL is the result either of acquired mutations in the <em>BCL6</em> promoter that prevent BCL6 binding or of translocations that place <em>BCL6</em> under the control of heterologous transcriptional regulatory elements that are not subject to BCL6 autoregulation [<a href="#rid4">4</a>]. Overexpression of BCL6 in B cell lymphoma cells leads to downregulation of BCL6 target genes, including the <em>TP53</em> tumor suppressor gene, which may be one way in which BCL6 protects cells from undergoing apoptosis in response to DNA damage  (<a class="graphic graphic_figure graphicRef62109" href="/z/d/graphic/62109.html" rel="external">figure 2</a>).</p><p>The combined frequency of <em>BCL6</em> mutations and rearrangements approaches 100 percent in DLBCL cases, suggesting that structural alterations of the 5' noncoding region of the <em>BCL6</em> gene are necessary for the development of these tumors [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H4"><span class="h2">BCL6 action</span><span class="headingEndMark"> — </span>The B cell lymphoma 6 (<em>BCL6</em>) gene, located at band 3q27, encodes a 95 kD nuclear phosphoprotein of the BTB-POZ transcription factor family [<a href="#rid6">6</a>]. BCL6 contains six zinc-finger motifs (which bind to its DNA recognition sequence), a POZ transrepression domain, and a second repression domain [<a href="#rid7">7</a>]. The net effect is that BCL6 is a potent repressor of transcription [<a href="#rid8">8</a>]. In addition to regulation of genes with <em>BCL6</em> binding sites, BCL6 can also mediate repression of genes that lack <em>BCL6</em> binding sites by associating with other DNA-binding factors [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H5"><span class="h3">BCL6 in normal cells</span><span class="headingEndMark"> — </span>BCL6 is expressed in mature germinal center B cells, but not in their differentiated cell progeny (plasma cells and memory B cells). It acts as a transcription repressor for many genes, including <em>BCL6</em> itself, through a negative feedback loop involving BCL6 binding sites in the <em>BCL6</em> promoter.</p><p>Overexpression of BCL6 in B cell lymphoma cell lines prevents the cells from undergoing apoptosis in response to DNA damage [<a href="#rid9">9-11</a>]. It is hypothesized that BCL6 expression permits the DNA strand breaks that are required for normal somatic hypermutation and class switching to proceed in the germinal center without triggering apoptosis [<a href="#rid12">12</a>]. BCL6 may do so by suppressing the expression and activity of multiple components of the DNA damage response, including TP53 (an effector of apoptosis in response to DNA damage) and ATR, ATM, and CHK1 (DNA damage checkpoint proteins) [<a href="#rid13">13</a>]. Notably, BCL6 also downregulates the activity of several genes that can contribute to B cell transformation, such as <em>MYC</em> and <em>BCL2</em> [<a href="#rid14">14</a>]; these anti-oncogenic activities of BCL6 are frequently lost in DLBCL, sometimes through mutations or translocations involving <em>MYC</em> and <em>BCL2</em> that abrogate their regulation by BCL6. BCL6 expression must subsequently be downregulated for normal germinal center B cells to exit the germinal center and progress to the post-germinal center phase of B development [<a href="#rid15">15-17</a>].</p><p><em>BCL6</em> knockout mice cannot form germinal centers and have impaired T cell-dependent antibody responses, indicating that BCL6 is required for germinal center formation [<a href="#rid18">18</a>]. Transgenic mice engineered to overexpress <em>BCL6</em> from the immunoglobulin heavy chain promoter, thereby mimicking the (3;14) translocation seen in human DLBCL show increased germinal center formation and develop a lymphoproliferative disorder that frequently progresses to a DLBCL-like lymphoma [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H6"><span class="h3">BCL6 dysregulation in DLBCL</span><span class="headingEndMark"> — </span>As mentioned above, the <em>BCL6</em> gene is expressed in most cases of DLBCL. In some instances, this may merely reflect the stage of B cell differentiation at which the tumor cells arrest, but in approximately 30 percent of DLBCL it is the consequence of a translocation that places the gene under the control of a new promoter. In an additional subset of cases, BCL6 expression stems from or is enhanced by a mutation in the <em>BCL6</em> gene promoter that interferes with the BCL6-dependent negative autoregulatory loop for this gene. Persistent expression or overexpression of BCL6 results in several alterations in germinal center (GC) B cells that are believed to contribute to lymphomagenesis [<a href="#rid14">14,20</a>], including:</p><p class="bulletIndent1"><span class="glyph">●</span>Inhibition of cell cycle arrest, via repression of factors such as cyclin-dependent kinase inhibitor 1A.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Modulation of apoptosis through effects on BCL2 and caspases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dampening the DNA-damage response through downregulation of p53 and DNA damage checkpoint factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Promotion of expression of activation-induced cytosine deaminase (AID), an enzyme that contributes to genomic instability by participating directly in somatic hypermutation. BCL6 upregulates AID indirectly by inhibiting the expression of the micro-RNAs <em>miR-155</em> and <em>miR-361</em>, which suppress AID expression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhibition of egress from germinal centers, by suppressing the expression of PRDM1 (also known as BLIMP-1), a transcription factor that promotes plasma cell differentiation.</p><p></p><p>This has led to the hypothesis that cells unable to downregulate <em>BCL6</em> (either due to a mutation or translocation) are unable to exit the germinal center and differentiate; this block in differentiation may promote lymphomagenesis by holding cells in a proliferative, genomically unstable state (due to persistent expression of activation-induced cytosine deaminase [AID], an enzyme that causes somatic hypermutation, and downregulation of p53 and other DNA damage response factors).</p><p class="headingAnchor" id="H7"><span class="h2">Genetic alterations that upregulate BCL6</span></p><p class="headingAnchor" id="H8"><span class="h3">BCL6 mutations</span><span class="headingEndMark"> — </span>Approximately 70 percent of DLBCLs have multiple, often biallelic, mutations in the <em>BCL6</em> gene that cluster in its 5' non-coding region, within 2 kb of the transcription initiation site [<a href="#rid5">5,21</a>]. These mutations occur frequently in systemic nodal DLBCL, primary extranodal DLBCL, CD5(+) DLBCL, CD30(+) DLBCL, and primary splenic DLBCL, but generally not in primary mediastinal large B cell lymphoma [<a href="#rid21">21</a>]. (See <a class="local">'Mediastinal large B cell lymphoma'</a> below.)</p><p><em>BCL6 </em>mutations also occur in a small proportion of normal germinal center B cells, 30 percent of follicular lymphomas, and varying percentages of chronic lymphocytic leukemia/small lymphocytic lymphoma, Burkitt lymphoma, and MALT lymphoma. Except for a subset of follicular lymphomas, they are generally independent of translocation to immunoglobulin (Ig) loci or other rearrangements of the <em>BCL6 </em>locus. The mutations are often single base substitutions, most commonly transitions, and bear the molecular signature of mutations that are induced by AID as part of the normal process of somatic hypermutation [<a href="#rid10">10,11</a>]. In tumors with <em>BCL6 </em>translocation, they occur more commonly on the der(14q32) translocated allele [<a href="#rid22">22</a>].</p><p>The genomic sequences most frequently involved in these mutations are adjacent to the <em>BCL6 </em>promoter and overlap with the major cluster of chromosomal breakpoints, suggesting that mutations and rearrangements may both be selected for their ability to alter that region, which appears to be important for the negative autoregulation of <em>BCL6 </em>[<a href="#rid5">5,10,11</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Translocations involving the BCL6 gene</span><span class="headingEndMark"> — </span>Approximately 30 percent of DLBCLs in immunocompetent hosts and 20 percent of AIDS-related cases display rearrangement of the <em>BCL6</em> gene on chromosome 3q27 [<a href="#rid6">6,23-25</a>]. Reciprocal translocations juxtapose 3q27 to one of several chromosomal sites, including 14q32 (IgH), 2p11 (Ig kappa), 22q11 (Ig lambda), as well as more than 10 other chromosomal sites unrelated to antigen receptor loci. (See  <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Genetic features'</a>.)</p><p>The chromosomal translocation breakpoints lying within the 5' region flanking <em>BCL6</em> usually fall within the noncoding first exon or first intron [<a href="#rid6">6,26</a>]. In a minority of cases, the chromosomal breakpoint is not located in the immediate proximity of the <em>BCL6</em> gene, suggesting that more distant breakpoint clusters exist. In all cases displaying direct involvement of <em>BCL6</em>, the coding region is left intact, whereas the 5' regulatory region, containing the promoter sequences, is either completely removed (in case of breaks within the first exon or intron) or truncated [<a href="#rid26">26</a>]. As a result, all of the coding exons of <em>BCL6</em> are linked to sequences from heterologous genes, placing <em>BCL6</em> under the control of constitutively active regulatory sequences that drive <em>BCL6</em> overexpression. Most commonly, these alterations result in the juxtaposition of heterologous promoters to the <em>BCL6 </em>coding domain, leading to increased <em>BCL6 </em>expression by a mechanism called promoter substitution [<a href="#rid26">26,27</a>]. Dysregulated expression of the translocation partner gene, now regulated by the <em>BCL6</em> promoter, may also occur [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H175770210"><span class="h3">Other alterations that upregulate BCL6</span><span class="headingEndMark"> — </span>Other reported indirect mechanisms leading to hyperactivity of BCL6 in DLBCL include gain-of-function mutations in <em>MEF2B</em>, which encodes a transcription factor that upregulates <em>BCL6</em> expression [<a href="#rid28">28</a>]; and loss-of-function mutations in factors that regulate BCL6 through post-translational modifications, such as FBXO11 (which promotes BCL6 ubiquitylation and degradation) [<a href="#rid29">29</a>]; and CREBBP and EP300, which acetylate and thereby inactivate BCL6 [<a href="#rid30">30,31</a>].</p><p class="headingAnchor" id="H10"><span class="h1">TP53 DOWNREGULATION</span><span class="headingEndMark"> — </span>Up to 20 percent of DLBCL demonstrate mutations or deletions of the <em>TP53</em> tumor suppressor gene (the gene that encodes p53) [<a href="#rid32">32,33</a>]. In addition, <em>TP53</em> transcription is at least partially controlled by the BCL6 protein, which is often overexpressed in DLBCL. The normal ("wild type") <em>TP53</em> gene, located at 17p13.1, produces a DNA-binding protein, p53, that induces a variety of growth-limiting responses, including cell cycle arrest (in order to facilitate DNA repair), apoptosis, senescence, and differentiation. Downregulation of <em>TP53</em> expression or expression of mutant p53 protein results in a loss of the normal growth-limiting activities of this gene.</p><p class="headingAnchor" id="H11"><span class="h2">Effect of BCL6 on TP53</span><span class="headingEndMark"> — </span>As mentioned above, the B cell leukemia 6 (BCL6) protein is a transcription repressor that decreases the expression of many genes, including itself and the tumor suppressor gene <em>TP53</em>. Mutations in the <em>TP53</em> gene of DLBCL are seen almost exclusively in cases without <em>BCL6</em> translocations, suggesting that the aberrant expression of BCL6 circumvents the selective pressure for <em>TP53</em> mutations [<a href="#rid12">12</a>]. (See <a class="local">'BCL6 dysregulation in DLBCL'</a> above.)</p><p class="headingAnchor" id="H12"><span class="h2">TP53 mutations</span><span class="headingEndMark"> — </span>Approximately 20 percent of patients with DLBCL exhibit <em>TP53</em> mutations [<a href="#rid32">32-34</a>]. Mutations are seen in sequences of the <em>TP53</em> gene that encode the non-DNA binding domain regions or different DNA-binding domain regions including Loop-L3, Loop-Sheet-Helix, and Loop-L2 [<a href="#rid34">34</a>]. The region involved may have prognostic implications [<a href="#rid32">32,33</a>].</p><p>As an example, a multicenter study demonstrated <em>TP53</em> mutations in 102 of 477 (21 percent) cases of DLBCL [<a href="#rid34">34</a>]. The presence of a <em>TP53 </em>mutation was associated with worse overall survival. Furthermore, the location of the mutation within the p53 protein appeared to be important, with DNA binding domain mutations associated with the worst outcome, followed by mutations of the Loop-Sheet-Helix and Loop-L3. Mutations in Loop-L2 did not affect survival. The presence of a DNA binding domain mutation in <em>TP53</em> was an independent predictor of survival, suggesting that these mutations are important either in DLBCL pathogenesis or in DLBCL susceptibility to chemotherapy.</p><p>The p53 protein activates the expression of the <em>CDKN1A</em> gene, which encodes the p21 cyclin dependent kinase inhibitor (CIP1/WAF1). Expression of p21 appears to be an independent predictor of failure-free and overall survival in DLBCL treated with R-CHOP. As an example, a prospective intergroup trial demonstrated that the addition of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> to standard chemotherapy had no effect on the clinical outcomes of patients with p21 negative tumors, but significantly improved the failure-free survival of patients with p21 positive tumors [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H13"><span class="h1">OTHER MECHANISMS</span></p><p class="headingAnchor" id="H14"><span class="h2">Aberrant somatic hypermutation</span><span class="headingEndMark"> — </span>Somatic hypermutation is the introduction of point mutations and small deletions or insertions, usually affecting the variable regions of immunoglobulin heavy chain genes of germinal center B cells. Somatic hypermutation is a key component of affinity maturation during humoral immune responses. In normal germinal center cells, somatic hypermutation also targets the 5' regions of some non-immunoglobulin genes, including <em>BCL6</em> [<a href="#rid11">11,36,37</a>]. Approximately half of DLBCL cases demonstrate aberrant somatic hypermutation targeting proto-oncogenes involved in cell proliferation, differentiation, and signal transduction. (See  <a class="medical medical_review" href="/z/d/html/4711.html" rel="external">"Overview of the pathobiology of the non-Hodgkin lymphomas", section on 'B cell germinal center reaction'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, aberrant somatic hypermutation was found to target multiple loci, including proto-oncogenes in more than 50 percent of cases of DLBCL, suggesting a malfunction of somatic hypermutation [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study reported that approximately 25 percent of DLBCLs demonstrate somatic hypermutation resulting in the inactivation of SOCS1 (an inhibitor of JAK/STAT signaling), resulting in deregulated STAT activity [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The importance of aberrant somatic hypermutation is also supported by studies of lymphomagenesis in mice engineered to overexpress <em>BCL6</em> in germinal center B cells. In these animals, inactivation of somatic hypermutation through knockout of the activation-induced cytosine deaminase (AID) gene markedly suppresses the appearance of DLBCL [<a href="#rid40">40</a>]. </p><p></p><p>Of further interest, some of the hypermutable genes are also susceptible to chromosomal translocations in the same regions, consistent with a role for hypermutation in generating DNA double-strand breaks that may lead to rearrangements such as translocations. By mutating multiple genes, and possibly by favoring chromosomal translocations, aberrant hypermutation may be a major contributor to lymphomagenesis.</p><p class="headingAnchor" id="H15"><span class="h2">BCL2 overexpression</span><span class="headingEndMark"> — </span>B cell leukemia/lymphoma 2 (<em>BCL2</em>) is an oncogene that blocks programmed cell death (apoptosis), leading to prolonged cell survival. BCL2 overexpression is often the result of a (14;18) translocation that places <em>BCL2</em> under the control of immunoglobulin regulatory elements. This translocation is common in follicular lymphoma, but is also seen in up to 30 percent of DLBCL, especially germinal center-like DLBCL. (See <a class="local">'Gene expression heterogeneity of DLBCL'</a> below and  <a class="medical medical_review" href="/z/d/html/16646.html" rel="external">"Pathobiology of follicular lymphoma", section on 'Translocations involving BCL-2'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">MYC overexpression</span><span class="headingEndMark"> — </span><em>MYC</em> gene rearrangements occur in 5 to 15 percent of DLBCL [<a href="#rid41">41</a>]. This translocation has the same molecular consequence as those seen in Burkitt lymphoma, namely overexpression of MYC protein. Approximately 80 percent of these rearrangements involve the <em>IGH</em> locus, while the other 20 percent involve the Ig light chain loci or non-immunoglobulin genes, such as <em>BCL6, ZCCHC7, </em>and<em> RFTN1</em> [<a href="#rid42">42</a>]. DLBCLs with <em>MYC</em> rearrangements appear to have a particularly poor prognosis [<a href="#rid41">41,43</a>]. Amplification and/or overexpression of the <em>MYC</em> gene without gene rearrangement has also been described in DLBCL and is also associated with poor prognosis [<a href="#rid41">41,44-46</a>]. As an example, one study reported that 38 percent of DLBCL tumors demonstrated an increase in the <em>MYC</em> gene copy number, which was also associated with increased <em>MYC</em> mRNA levels [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/4700.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma", section on 'Translocations involving the MYC oncogene'</a>.)</p><p class="headingAnchor" id="H175770310"><span class="h2">Immune evasion</span><span class="headingEndMark"> — </span>Evasion of host immunity is considered a hallmark of cancer, and insight into how tumors evade host immunity has led to successful immunotargeting of many tumors with agents that negate tumor cell evasion mechanisms. Several mechanisms of immunoevasion have been described in DLBCL. Approximately 60 percent of DLBCL cases fail to express class I MHC complexes that are needed for immunosurveillance by cytotoxic T cells. Mechanisms include loss-of-function mutations in beta-2 microglobulin (<em>B2M</em>), <em>HLA-A, HLA-B, </em>and<em> HLA-C</em>, and defective transport of B2M or HLA-I molecules [<a href="#rid47">47,48</a>]. Similarly, loss of HLA class I expression is often accompanied by loss of expression of CD58, which is needed for immune surveillance by natural killer (NK) cells [<a href="#rid47">47</a>]. A comprehensive genomic analysis of 304 DLBCLs reported that 74 percent exhibited genetic alterations that are predicted to enhance immunoevasion [<a href="#rid49">49</a>]. </p><p class="headingAnchor" id="H2083172436"><span class="h2">Abnormal lymphocyte trafficking</span><span class="headingEndMark"> — </span>Normal lymphocytes migrate through the body in response to complex microenvironmental cues. Abnormal trafficking may impact lymphocyte development and play a role in the pathogenesis of DLBCL. As an example, local gradients of the lipid metabolite sphingosine-1-phosphate (S1P) help to coordinate migration necessary for affinity maturation and class switch recombination. In one hypothesis, the population of maturing B cells is kept in check by the S1P receptor (S1PR2), which inhibits migration, trapping the vast majority of cells in the germinal center and limiting survival.  </p><p>Reports have demonstrated abnormalities in S1PR2 in DLBCL. S1PR2 deficiency due to mutations in the <em>S1PR2</em> promoter is common in germinal center B cell type DLBCL [<a href="#rid50">50-52</a>]. In contrast, <em>S1PR2</em> promoter mutations are not seen in activated B cell (ABC) type DLBCL. Instead, <em>S1PR2</em> appears to be silenced in ABC DLBCL by the transcriptional regulator FOXP1 [<a href="#rid53">53</a>]. An additional 15 to 20 percent of germinal center B cell type DLBCLs is associated with mutations in <em>GNA13</em>, a gene encoding a small G protein that regulates B cell motility [<a href="#rid52">52</a>]. These observations support the role of acquired alterations that affect motility and trafficking as common feature of DLBCL. </p><p>Another example of genetic lesions that affect the trafficking of DLBCL cells are mutations in <em>P2RY8</em>, a gene encoding a G-protein coupled receptor that inhibits the migration of germinal center B cells. Loss-of-function mutations in <em>P2RY8</em> may allow malignant germinal center B cells to "escape" from the germinal center microenvironment, possibly enhancing their spread to other sites within lymph nodes and other tissues [<a href="#rid54">54</a>]. Mutations in <em>GNA13</em>, which encodes the G-protein that is associated with P2RY8 in germinal center B cells, also are found in DLBCL, further linking signals involving P2RY8 to DLBCL migration.</p><p class="headingAnchor" id="H17"><span class="h1">HETEROGENEITY OF DLBCL</span><span class="headingEndMark"> — </span>As described above, the diagnostic category of "diffuse large B cell lymphoma" is heterogeneous in terms of morphology, genetics, and biologic behavior. While a number of clinicopathologic entities that are sufficiently distinct to be considered separate diagnostic categories (eg, intravascular lymphoma) are now recognized, it is difficult to reliably subclassify DLBCL into morphologic variants (ie, centroblastic lymphoma and immunoblastic lymphoma) [<a href="#rid55">55</a>]. By contrast, molecular subtyping appears to identify subtypes with different prognoses. (See  <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Morphology'</a> and  <a class="medical medical_review" href="/z/d/html/83821.html" rel="external">"Prognosis of diffuse large B cell lymphoma", section on 'Gene expression profiling'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Molecular heterogeneity of DLBCL</span><span class="headingEndMark"> — </span>The biologic diversity of DLBCL has been validated by the identification of multiple genetic subtypes. Early molecular subclassifications were based on the presence of <em>BCL2</em> or <em>BC6</em> gene rearrangements to create three distinct subtypes, which may have different prognoses [<a href="#rid56">56</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><em>BCL6</em>-positive DLBCL (40 percent): Rearrangements of <em>BCL6</em> in the absence of other known genetic lesions. <em>BCL6</em>-positive DLBCL are de novo lymphomas, presenting without a previous history of follicular lymphoma (FL). (See <a class="local">'Aberrant BCL6 expression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>BCL2</em>-positive DLBCL: B cell leukemia/lymphoma 2 (<em>BCL2</em>) can be activated either alone or in combination with <em>TP53</em> mutations. <em>BCL2</em>-positive DLBCL carrying <em>TP53</em> mutations derive from the histologic transformation of a previous FL, whereas the histogenesis of <em>BCL2</em>-positive/<em>TP53</em>-negative DLBCL is controversial. (See <a class="local">'BCL2 overexpression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cases with germline <em>BCL2 </em>and<em> BCL6</em> genes.</p><p></p><p>In one study, cases associated with <em>BCL6</em> rearrangements displayed the most favorable prognosis, whereas cases carrying <em>BCL2</em> translocations had the poorest outcome [<a href="#rid56">56</a>]. The third group (ie, cases without rearrangements of <em>BCL6 </em>and<em> BCL2</em>) displayed an intermediate prognosis. Of interest, grade IIIB follicular lymphoma, which has an aggressive clinical course similar to DLBCL, demonstrated a pattern of cytogenetic changes similar to DLBCL, suggesting a close relationship between these two tumor subtypes [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma", section on 'Tumor grade'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Gene expression heterogeneity of DLBCL</span><span class="headingEndMark"> — </span>Gene expression has been extensively studied in DLBCL using microarray technology. One line of investigation that has come to dominate the field uses supervised clustering to sort DLBCLs based on likely cell of origin. This work has characterized three types of DLBCL: germinal center B cell-like (GCB), activated B cell-like (ABC), and a not-otherwise-specified type 3  (<a class="graphic graphic_figure graphicRef80736" href="/z/d/graphic/80736.html" rel="external">figure 1</a>) [<a href="#rid58">58-61</a>]. The optimal combination of immunohistochemical markers that can reliably separate GCB from ABC type DLBCL is controversial and remains in flux [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/83821.html" rel="external">"Prognosis of diffuse large B cell lymphoma", section on 'Overview'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Germinal center B cell-like – The germinal center B cell-like (GCB) DLBCL has a gene expression profile characteristic of normal germinal center B cells. The immunoglobulin gene demonstrates intraclonal heterogeneity and ongoing somatic hypermutation [<a href="#rid63">63</a>]. This subtype is often associated with the (14;18) translocation (<em>IgH/BCL2</em> fusion gene) typical of follicular lymphoma and amplifications of the locus on chromosome 2 which codes for the <em>REL</em> oncogene. GCB has also been associated with gains of chromosome 12q12 [<a href="#rid64">64</a>]. (See <a class="local">'BCL2 overexpression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activated B cell-like – The activated B cell-like (ABC) DLBCL demonstrates a gene expression profile similar to that of post-germinal center activated B cells. The immunoglobulin gene demonstrates intraclonal homogeneity [<a href="#rid63">63</a>]. The ABC subtype is associated with loss of 6q21, trisomy 3, and gains of 3q and 18q21-22 [<a href="#rid64">64,65</a>]. The commonly deleted locus on 6q includes the gene for the tumor suppressor <em>PRDM1</em> (BLIMP-1), a master regulator of the differentiation of mature B lymphocytes into plasma cells [<a href="#rid66">66</a>]. Loss of <em>PRDM1</em> may lead to inhibition of terminal differentiation, one possible pathogenetic pathway in DLBCL. ABC DLBCLs also have high expression of PDE4B, which prevents cAMP from triggering apoptosis [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1">In addition, ABC DLBCLs have high expression and constitutive activity of the nuclear factor kappa B (NF-KB) complex involved in the B cell receptor (BCR) signaling pathway [<a href="#rid4">4,59,68</a>]. ABC DLBCLs carry somatic mutations in multiple genes that are positive regulators of NF-kappaB, including <em>CARD11, TRAF2, </em>and<em> TRAF5</em> [<a href="#rid69">69</a>]. The survival of ABC DLBCLs without <em>CARD11</em> mutations appears to be dependent upon the expression of another BCR signaling component known as Bruton tyrosine kinase (BTK) [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/3985.html" rel="external">"Toll-like receptors: Roles in disease and therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type III – Type III DLBCL is a heterogeneous group of tumors that have gene expression profiles that differ from germinal center and post-germinal center B cells. Its pathobiology is unknown.</p><p></p><p>An alternative molecular classification scheme generated by the unsupervised clustering of gene expression profiles divides DLBCL into three groups characterized by the expression of genes involved in B cell signaling (BCR), oxidative phosphorylation, or the host immune response [<a href="#rid70">70</a>]. Of note, the tyrosine kinase SYK, which participates in BCR signaling and is selectively active in BCR-type, is a proposed therapeutic target in DLBCL and certain other B cell neoplasms [<a href="#rid71">71,72</a>]. Supervised analysis of DLBCL expression profiles from the same group identified expression of PKC-beta as a marker of poor outcome [<a href="#rid73">73</a>], a finding also noted by others [<a href="#rid74">74</a>]. This association has led to trials of PKC-beta inhibitors (eg, enzastaurin) in DLBCL.</p><p>The use of gene expression profiling in the diagnosis of DLBCL and the determination of prognosis has been limited to date by the need for fresh tissue for profiling on gene arrays. New approaches that allow subtyping of DLBCL using RNA isolated from formalin-fixed paraffin-embedded tissues have emerged and are being used clinically at some centers [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/z/d/html/83821.html" rel="external">"Prognosis of diffuse large B cell lymphoma", section on 'Cell of origin studies'</a>.)</p><p class="headingAnchor" id="H4182064207"><span class="h1">INSIGHTS FROM DEEP SEQUENCING OF DLBCL GENOMES</span><span class="headingEndMark"> — </span>Deep sequencing of DNA is providing new insights into the pathobiology of DLBCL, which may lead to new therapies and/or establish new genetic classification systems for DLBCL. </p><p>More than 150 recurrent mutations have been identified in DLBCL [<a href="#rid49">49,76,77</a>]. Some of the most frequent mutations involve genes that regulate histone modifications, such as <em>MLL2, MEF2B, EZH2, </em>and<em> CREBBP</em> [<a href="#rid30">30,78</a>]. This suggests that epigenetic alterations play an important role in the pathobiology of DLBCL and may provide new treatments because many epigenetic regulators are enzymes that can be targeted with drugs.</p><p>These studies may lead to a new genetic classification system for DLBCL. Various classification systems have been proposed, but there is not yet consensus regarding a preferred model nor clear evidence of advantages over current methods for categorizing DLBCL. </p><p>Examples of proposed models include:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 574 DLBCL samples, four subtypes were identified that differed by gene-expression signature, phenotype, and response to immunochemotherapy [<a href="#rid77">77</a>]. The four major subtypes were described as MCD (mutations of <em>MYD88L265P</em> and <em>CD79B</em>), BN2 (<em>BCL6</em> fusions and <em>NOTCH2</em> mutations), N1 (<em>NOTCH1</em> mutations), and EZB (<em>EZH2</em> mutations and <em>BCL2</em> translocations).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of 304 DLBCL specimens identified five genetic subtypes that were associated with distinct outcomes and appeared to convey prognostic information independent of the International Prognostic Index [<a href="#rid49">49</a>]. The categories were identified as: low-risk activated B cell (ABC) of extrafollicular/marginal zone origin; two distinct subsets of germinal center B cell (GCB) with different outcomes and targetable alterations; and an ABC/GCB-independent group with biallelic inactivation of <em>TP53</em>, <em>CDKN2A</em> loss, and associated genomic instability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A population-based study of 928 patients with DLBCL resolved five distinct molecular subtypes by sequencing 293 genes associated with hematologic malignancies [<a href="#rid79">79</a>]. The <em>MYD88</em> category was associated with a poor prognosis and was strongly associated with the ABC cell-of-origin (COO) category. The <em>BCL2</em> category was strongly associated with the GCB category and a generally good prognosis; this category included most cases of transformed follicular lymphoma or concurrent follicular lymphoma. The <em>SOCS1/SGK1</em> category had the most favorable prognosis and shared molecular features with primary mediastinal B cell lymphoma, while the remaining categories had less distinctive prognostic and subtype associations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of 1,001 specimens identified 150 genetic driver mutations, and a prognostic model was developed that outperformed current methods based on COO, International Prognostic Index, and dual MYC and BCL2 expression [<a href="#rid76">76</a>].</p><p></p><p>The pattern of somatic mutations in DLBCL varies according to the COO (GCB versus ABC types) [<a href="#rid80">80</a>]. Both classes of DLBCL are equally likely to have mutations involving <em>BCL6, TP53,</em> genes that encode immunosurveillance factors, and genes that are involved in regulation of the epigenome. However, GCB tumors are more likely to have mutations in the epigenetic regulator <em>EZH2, GNA13</em> (a putative regulator of cell motility), and <em>BCL2</em> translocations, whereas ABC-type DLBCLs are more often associated with mutations in genes that increase B cell receptor signaling and activation of the pro-survival transcription factor NF-kB, such as <em>MYD88, CD79A, CARD11, </em>and<em> TNFAIP3</em> (also known as A20). Whole genome sequencing has also demonstrated widespread genomic rearrangements and evidence of chromothripsis (ie, local chromosome shattering) [<a href="#rid50">50</a>]. Based on the analysis of subclonal variants within the same tumor, it appears that tumors continue to acquire mutations throughout their initial outgrowth. Mutations in genes such as <em>EZH2, MYD88, CARD11, </em>and<em> CD79A</em> previously thought to initiate tumorigenesis are among the events that are sometimes present only in subclones, indicating that these mutations may also occur after tumor initiation.</p><p class="headingAnchor" id="H20"><span class="h1">MEDIASTINAL LARGE B CELL LYMPHOMA</span><span class="headingEndMark"> — </span>Primary large B cell lymphoma of the mediastinum (PMBL) is a variant of DLBCL arising in the mediastinum from the thymic (medullary) B cell. As long-suspected on clinical grounds, biological data suggest that PMBL should be separated from DLBCL [<a href="#rid81">81</a>]. Specifically, the gene expression profile of PMBL is more similar to that of classic Hodgkin lymphoma (cHL) than that of DLBCL [<a href="#rid29">29,82</a>], and the genetic drivers in PMBL are somewhat distinct from those found in DLBCL.</p><p>Molecular changes that are closely associated with PMBL include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Signaling abnormalities</strong> – Constitutive activation of the JAK-STAT and NF-kB signaling pathways are hallmarks of PMBL [<a href="#rid83">83</a>]. As an example, whole exome sequencing of 95 PMBL tumors identified recurrent mutations in JAK-STAT, NF-kB, and interferon response factor (IRF) signaling pathways [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune evasion</strong> – PMBL is associated with genomic abnormalities that enable immune evasion. Numerical and structural genomic changes of chromosome 9p24.1 (which includes loci that encode PD-L1 and PD-L2) and alterations to CIITA (the master transcriptional regulator of major histocompatibility complex class [MHC] II gene expression) are thought to contribute to PMBL pathogenesis by fostering immune evasion [<a href="#rid81">81,84-87</a>]. </p><p></p><p class="headingAnchor" id="H953318"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/691.html" rel="external">"Patient education: Diffuse large B cell lymphoma in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma. The molecular pathogenesis of DLBCL is a complex, multistep process leading to the outgrowth of a malignant clone of germinal or post-germinal B cell origin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heterogeneity of DLBCL</strong> – DLBCL is a heterogeneous clinicopathologic entity that includes tumors derived from germinal center B cells or post-germinal center B cells (also called activated B cells)  (<a class="graphic graphic_figure graphicRef80736" href="/z/d/graphic/80736.html" rel="external">figure 1</a>). (See <a class="local">'Cell of Origin'</a> above and <a class="local">'Heterogeneity of DLBCL'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BCL6</em></strong><strong> mutations in DLBCL</strong> – The majority of DLBCL tumors demonstrates translocations or mutations that result in the increased expression of the B cell lymphoma 6 (<em>BCL6</em>) gene. Overexpression of BCL6 leads to downregulation of target genes, including the <em>TP53</em> tumor suppressor gene, which prevents the cells from undergoing apoptosis in response to DNA damage  (<a class="graphic graphic_figure graphicRef62109" href="/z/d/graphic/62109.html" rel="external">figure 2</a>). (See <a class="local">'Aberrant BCL6 expression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>TP53</em></strong><strong> (p53) mutations</strong> – Up to 20 percent of DLBCL demonstrate mutations or deletions of the <em>TP53</em> tumor suppressor gene. In addition, <em>TP53</em> transcription is at least partially controlled by BCL6, which encodes a transcriptional repressor. Downregulation of <em>TP53</em> expression or expression of mutant p53 products results in a loss of the normal growth-limiting activities of this gene. (See <a class="local">'TP53 downregulation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other contributors to pathogenesis of DLBCL</strong> – Other mechanisms important in the pathogenesis of subsets of DLBCL include aberrant somatic hypermutation, BCL2 overexpression, MYC overexpression, evasion of host immunity, and altered tumor cell motility/trafficking. (See <a class="local">'Other mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary large B cell lymphoma of the mediastinum (PMBL)</strong> – PMBL is a variant of DLBCL that arises in the mediastinum from the thymic (medullary) B cell. The pathogenesis of PMBL appears to be closer to that of classical Hodgkin lymphoma than that of DLBCL, and involves activation of JAK-STAT and NF-KB signaling and acquisition of genetic lesions that allow the tumor cells to escape from immune surveillance. (See <a class="local">'Mediastinal large B cell lymphoma'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li><a class="nounderline abstract_t">Stevenson F, Sahota S, Zhu D, et al. Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. Immunol Rev 1998; 162:247.</a></li><li><a class="nounderline abstract_t">Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010; 362:1417.</a></li><li><a class="nounderline abstract_t">Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463:88.</a></li><li><a class="nounderline abstract_t">Migliazza A, Martinotti S, Chen W, et al. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci U S A 1995; 92:12520.</a></li><li><a class="nounderline abstract_t">Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993; 262:747.</a></li><li><a class="nounderline abstract_t">Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci U S A 1996; 93:6947.</a></li><li><a class="nounderline abstract_t">Parekh S, Polo JM, Shaknovich R, et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood 2007; 110:2067.</a></li><li><a class="nounderline abstract_t">Phan RT, Saito M, Basso K, et al. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 2005; 6:1054.</a></li><li><a class="nounderline abstract_t">Shen HM, Peters A, Baron B, et al. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 1998; 280:1750.</a></li><li><a class="nounderline abstract_t">Pasqualucci L, Migliazza A, Fracchiolla N, et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci U S A 1998; 95:11816.</a></li><li><a class="nounderline abstract_t">Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004; 432:635.</a></li><li><a class="nounderline abstract_t">Basso K, Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol 2015; 15:172.</a></li><li><a class="nounderline abstract_t">Ci W, Polo JM, Cerchietti L, et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood 2009; 113:5536.</a></li><li><a class="nounderline abstract_t">Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. Blood 1995; 86:45.</a></li><li><a class="nounderline abstract_t">Tunyaplin C, Shaffer AL, Angelin-Duclos CD, et al. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol 2004; 173:1158.</a></li><li><a class="nounderline abstract_t">Fearon DT, Manders PM, Wagner SD. Bcl-6 uncouples B lymphocyte proliferation from differentiation. Adv Exp Med Biol 2002; 512:21.</a></li><li><a class="nounderline abstract_t">Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet 1997; 16:161.</a></li><li><a class="nounderline abstract_t">Cattoretti G, Pasqualucci L, Ballon G, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 2005; 7:445.</a></li><li><a class="nounderline abstract_t">Basso K, Saito M, Sumazin P, et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood 2010; 115:975.</a></li><li><a class="nounderline abstract_t">Capello D, Vitolo U, Pasqualucci L, et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood 2000; 95:651.</a></li><li><a class="nounderline abstract_t">Jardin F, Bastard C, Contentin N, et al. Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3;14)(q27;q32) non-Hodgkin B-cell lymphoma. Blood 2003; 102:1872.</a></li><li><a class="nounderline abstract_t">Lo Coco F, Ye BH, Lista F, et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 1994; 83:1757.</a></li><li><a class="nounderline abstract_t">Gaidano G, Lo Coco F, Ye BH, et al. Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype. Blood 1994; 84:397.</a></li><li><a class="nounderline abstract_t">Dalla-Favera R, Migliazza A, Chang CC, et al. Molecular pathogenesis of B cell malignancy: the role of BCL-6. Curr Top Microbiol Immunol 1999; 246:257.</a></li><li><a class="nounderline abstract_t">Ye BH, Chaganti S, Chang CC, et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J 1995; 14:6209.</a></li><li><a class="nounderline abstract_t">Kaneita Y, Yoshida S, Ishiguro N, et al. Detection of reciprocal fusion 5'-BCL6/partner-3' transcripts in lymphomas exhibiting reciprocal BCL6 translocations. Br J Haematol 2001; 113:803.</a></li><li><a class="nounderline abstract_t">Ying CY, Dominguez-Sola D, Fabi M, et al. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nat Immunol 2013; 14:1084.</a></li><li><a class="nounderline abstract_t">Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102:3871.</a></li><li><a class="nounderline abstract_t">Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471:189.</a></li><li><a class="nounderline abstract_t">Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002; 32:606.</a></li><li><a class="nounderline abstract_t">Koduru PR, Raju K, Vadmal V, et al. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 1997; 90:4078.</a></li><li><a class="nounderline abstract_t">Ichikawa A, Kinoshita T, Watanabe T, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997; 337:529.</a></li><li><a class="nounderline abstract_t">Young KH, Leroy K, Møller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008; 112:3088.</a></li><li><a class="nounderline abstract_t">Winter JN, Li S, Aurora V, et al. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clin Cancer Res 2010; 16:2435.</a></li><li><a class="nounderline abstract_t">Müschen M, Re D, Jungnickel B, et al. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J Exp Med 2000; 192:1833.</a></li><li><a class="nounderline abstract_t">Gordon MS, Kanegai CM, Doerr JR, Wall R. Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a). Proc Natl Acad Sci U S A 2003; 100:4126.</a></li><li><a class="nounderline abstract_t">Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001; 412:341.</a></li><li><a class="nounderline abstract_t">Mottok A, Renné C, Seifert M, et al. Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood 2009; 114:4503.</a></li><li><a class="nounderline abstract_t">Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet 2008; 40:108.</a></li><li><a class="nounderline abstract_t">Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28:3360.</a></li><li><a class="nounderline abstract_t">Chong LC, Ben-Neriah S, Slack GW, et al. High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. Blood Adv 2018; 2:2755.</a></li><li><a class="nounderline abstract_t">Akasaka T, Akasaka H, Ueda C, et al. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. J Clin Oncol 2000; 18:510.</a></li><li><a class="nounderline abstract_t">Kawasaki C, Ohshim K, Suzumiya J, et al. Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas. Leuk Lymphoma 2001; 42:1099.</a></li><li><a class="nounderline abstract_t">Sáez AI, Artiga MJ, Romero C, et al. Development of a real-time reverse transcription polymerase chain reaction assay for c-myc expression that allows the identification of a subset of c-myc+ diffuse large B-cell lymphoma. Lab Invest 2003; 83:143.</a></li><li><a class="nounderline abstract_t">Stasik CJ, Nitta H, Zhang W, et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica 2010; 95:597.</a></li><li><a class="nounderline abstract_t">Challa-Malladi M, Lieu YK, Califano O, et al. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011; 20:728.</a></li><li><a class="nounderline abstract_t">Fangazio M, Dominguez-Sola D, Tabbo F, et al. Genetic mechanisms of immune escape in diffuse large B cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2014; 124:1692.</a></li><li><a class="nounderline abstract_t">Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018; 24:679.</a></li><li><a class="nounderline abstract_t">Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 2013; 122:1256.</a></li><li><a class="nounderline abstract_t">Cattoretti G, Mandelbaum J, Lee N, et al. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res 2009; 69:8686.</a></li><li><a class="nounderline abstract_t">Muppidi JR, Schmitz R, Green JA, et al. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma. Nature 2014; 516:254.</a></li><li><a class="nounderline abstract_t">Flori M, Schmid CA, Sumrall ET, et al. The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling. Blood 2016; 127:1438.</a></li><li><a class="nounderline abstract_t">Lu E, Wolfreys FD, Muppidi JR, et al. S-Geranylgeranyl-L-glutathione is a ligand for human B cell-confinement receptor P2RY8. Nature 2019; 567:244.</a></li><li><a class="nounderline abstract_t">Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.</a></li><li><a class="nounderline abstract_t">Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994; 331:74.</a></li><li><a class="nounderline abstract_t">Bosga-Bouwer AG, van Imhoff GW, Boonstra R, et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 2003; 101:1149.</a></li><li><a class="nounderline abstract_t">Morgensztern D, Martin MG, Lossos IS. Gene expression profiling in diffuse large B-cell lymphoma. Leuk Lymphoma 2007; 48:669.</a></li><li><a class="nounderline abstract_t">Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503.</a></li><li><a class="nounderline abstract_t">Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1937.</a></li><li><a class="nounderline abstract_t">Klapper W, Kreuz M, Kohler CW, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 2012; 119:1882.</a></li><li><a class="nounderline abstract_t">Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15:5494.</a></li><li><a class="nounderline abstract_t">Lossos IS, Alizadeh AA, Eisen MB, et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A 2000; 97:10209.</a></li><li><a class="nounderline abstract_t">Bea S, Zettl A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106:3183.</a></li><li><a class="nounderline abstract_t">Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42:181.</a></li><li><a class="nounderline abstract_t">Tam W, Gomez M, Chadburn A, et al. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006; 107:4090.</a></li><li><a class="nounderline abstract_t">Smith PG, Wang F, Wilkinson KN, et al. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 2005; 105:308.</a></li><li><a class="nounderline abstract_t">Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194:1861.</a></li><li><a class="nounderline abstract_t">Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459:717.</a></li><li><a class="nounderline abstract_t">Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105:1851.</a></li><li><a class="nounderline abstract_t">Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008; 111:2230.</a></li><li><a class="nounderline abstract_t">Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115:2578.</a></li><li><a class="nounderline abstract_t">Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8:68.</a></li><li><a class="nounderline abstract_t">Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005; 18:1377.</a></li><li><a class="nounderline abstract_t">Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123:1214.</a></li><li><a class="nounderline abstract_t">Reddy A, Zhang J, Davis NS, et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell 2017; 171:481.</a></li><li><a class="nounderline abstract_t">Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 2018; 378:1396.</a></li><li><a class="nounderline abstract_t">Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476:298.</a></li><li><a class="nounderline abstract_t">Lacy SE, Barrans SL, Beer PA, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood 2020; 135:1759.</a></li><li><a class="nounderline abstract_t">Pasqualucci L, Dalla-Favera R. The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol 2015; 52:67.</a></li><li><a class="nounderline abstract_t">Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011; 118:2659.</a></li><li><a class="nounderline abstract_t">Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198:851.</a></li><li><a class="nounderline abstract_t">Lees C, Keane C, Gandhi MK, Gunawardana J. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. Br J Haematol 2019; 185:25.</a></li><li><a class="nounderline abstract_t">Mottok A, Hung SS, Chavez EA, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood 2019; 134:802.</a></li><li><a class="nounderline abstract_t">Mottok A, Woolcock B, Chan FC, et al. Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression. Cell Rep 2015; 13:1418.</a></li><li><a class="nounderline abstract_t">Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116:3268.</a></li><li><a class="nounderline abstract_t">Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014; 123:2062.</a></li></ol></div><div id="topicVersionRevision">Topic 4722 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9602369" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393178" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Aggressive lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20054396" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618933" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8235596" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8692924" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17545502" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16142238" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9624052" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9751748" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15577913" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25712152" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Germinal centres and B cell lymphomagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19307668" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7795255" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : BCL-6 protein is expressed in germinal-center B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15240705" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12405183" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Bcl-6 uncouples B lymphocyte proliferation from differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9171827" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894265" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19965633" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10627476" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12775568" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3;14)(q27;q32) non-Hodgkin B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8142643" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8025268" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10396064" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Molecular pathogenesis of B cell malignancy: the role of BCL-6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8557040" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11380473" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Detection of reciprocal fusion 5'-BCL6/partner-3' transcripts in lymphomas exhibiting reciprocal BCL6 translocations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23974956" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12933571" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21390126" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Inactivating mutations of acetyltransferase genes in B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12402037" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acetylation inactivates the transcriptional repressor BCL6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9354678" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9262496" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18559976" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20371683" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11120779" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12651942" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11460166" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19734449" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18066064" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : AID is required for germinal center-derived lymphomagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20498406" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30348671" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10653866" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11697627" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12594230" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Development of a real-time reverse transcription polymerase chain reaction assay for c-myc expression that allows the identification of a subset of c-myc+ diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20378577" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22137796" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Combined genetic inactivation ofβ2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Genetic mechanisms of immune escape in diffuse large B cell lymphoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29713087" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23699601" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903857" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25274307" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26729899" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30842656" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : S-Geranylgeranyl-L-glutathione is a ligand for human B cell-confinement receptor P2RY8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8068936" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8208268" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12529293" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17454624" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Gene expression profiling in diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10676951" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12075054" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22238326" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706817" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10954754" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16046532" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20081860" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16424392" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15331441" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11748286" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19412164" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15550490" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18006696" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19965662" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11786909" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15920548" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24398326" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28985567" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29641966" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21796119" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32187361" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25805586" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The genetic landscape of diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21700770" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The molecular pathogenesis of primary mediastinal large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12975453" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30740662" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31292115" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26549456" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628145" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24497532" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
